Tumor Organoid as a Drug Screening Platform for Cancer Research

Area of Science:

• Biomedical Engineering
• Oncology
• Pharmacology

Background:

• 3D models are increasingly used for drug discovery, sensitivity assessment, and toxicity evaluation.
• Organoids, with their organotypic structure, are crucial for bridging basic research and clinical applications, particularly in cancer.
• Patient-derived organoids (PDOs) are widely adopted for drug testing despite standardization challenges.

Purpose of the Study:

• To review recent advancements in the application of organoids and tumoroids in cancer research and drug development.
• To highlight the potential of organoids in translational medicine and clinical trials.
• To discuss the use of organoids for high-throughput drug screening and personalized therapy development.

Main Methods:

• Review of recent scientific literature on organoid and tumoroid applications.
• Analysis of studies focusing on disease modeling using 3D cell cultures.
• Examination of organoid utility in drug screening, sensitivity assessment, and toxicity testing.

Main Results:

• Organoids facilitate accurate drug evaluation by mimicking organ reconstitution with controlled cellular features.
• Patient-derived organoids (PDOs) enable high-throughput analysis of compounds and personalized treatment strategies.
• Organoids and tumoroids are demonstrating significant potential in clinical trials for cancer research.

Conclusions:

• Organoids represent a powerful tool for advancing drug discovery and personalized medicine in oncology.
• The application of organoids in translational medicine is expanding, showing promise for improved patient outcomes.
• Despite challenges in standardization, organoids are becoming indispensable for preclinical drug testing and clinical trial applications.